These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12678728)

  • 41. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential Telomere-Related Pharmacological Targets.
    Berei J; Eckburg A; Miliavski E; Anderson AD; Miller RJ; Dein J; Giuffre AM; Tang D; Deb S; Racherla KS; Patel M; Vela MS; Puri N
    Curr Top Med Chem; 2020; 20(6):458-484. PubMed ID: 31916516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.
    Uziel O; Beery E; Dronichev V; Samocha K; Gryaznov S; Weiss L; Slavin S; Kushnir M; Nordenberg Y; Rabinowitz C; Rinkevich B; Zehavi T; Lahav M
    PLoS One; 2010 Feb; 5(2):e9132. PubMed ID: 20161752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
    Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
    Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Telomeres and telomerase as targets for anticancer drug development.
    Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The 'other' telomerase inhibitors: non-G-quadruplex interactive agent, non-antisense, non-reverse transcriptase telomerase inhibitors.
    Beltz LA
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):589-603. PubMed ID: 12678726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Telomerase inhibitors.
    Rowley PT; Tabler M
    Anticancer Res; 2000; 20(6B):4419-29. PubMed ID: 11205282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase.
    Gomez D; Aouali N; Renaud A; Douarre C; Shin-Ya K; Tazi J; Martinez S; Trentesaux C; Morjani H; Riou JF
    Cancer Res; 2003 Oct; 63(19):6149-53. PubMed ID: 14559794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telomere maintenance as a target for drug discovery.
    Sekaran V; Soares J; Jarstfer MB
    J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
    Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
    Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telomerase: a potential therapeutic target for cancer.
    Fletcher TM
    Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Telomerase and its potential for therapeutic intervention.
    Phatak P; Burger AM
    Br J Pharmacol; 2007 Dec; 152(7):1003-11. PubMed ID: 17603541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme.
    Elango H; Das RN; Saha A
    Future Med Chem; 2024; 16(19):2043-2067. PubMed ID: 39316718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Telomerase as a therapeutic target. Therapeutic potential of telomerase inhibitors.
    Double JA
    Methods Mol Biol; 2002; 191():209-16. PubMed ID: 11951608
    [No Abstract]   [Full Text] [Related]  

  • 56. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials.
    Relitti N; Saraswati AP; Federico S; Khan T; Brindisi M; Zisterer D; Brogi S; Gemma S; Butini S; Campiani G
    Curr Top Med Chem; 2020; 20(6):433-457. PubMed ID: 31894749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine.
    Philippi C; Loretz B; Schaefer UF; Lehr CM
    J Control Release; 2010 Sep; 146(2):228-40. PubMed ID: 20381558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity.
    Natarajan S; Chen Z; Wancewicz EV; Monia BP; Corey DR
    Oligonucleotides; 2004; 14(4):263-73. PubMed ID: 15665594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design of telomerase inhibitors for the treatment of cancer.
    Cairns D; Anderson RJ; Perry PJ; Jenkins TC
    Curr Pharm Des; 2002; 8(27):2491-504. PubMed ID: 12369943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies.
    Folini M; Zaffaroni N
    Curr Pharm Des; 2005; 11(9):1105-17. PubMed ID: 15853659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.